Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma Therapy in High-risk COVID-19 Patients
NCT04869072Phase 1Completed
- Sponsor
- University of Zurich
- Start
- Apr 2020
- Primary completion
- Nov 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19), sponsored by University of Zurich. Primary endpoints: Safety of CPT applied to COVID-19 patients at 48 hours, Improvement of respiratory frequency at 3 weeks and 8 more. Started Apr 2020; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04869072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04869072.